News | Contrast Media | February 04, 2016

Akrotome Imaging Receives $1.7M NIH Research Grant for Sprayable Cancer Imaging Agent

Imaging probes can be sprayed on cancerous tissue rather than delivered via IV, speeding FDA approval time and immediately alerting surgeons if all cancer cells have been removed

February 4, 2016 — Akrotome Imaging Inc. received a major award from the National Institutes of Health (NIH) in November to complete development and commercialization of its new imaging platform.

The $1.7M grant will fund the development of an imaging instrument and a fluorescent molecular probe that “lights up” many kinds of previously invisible cancer cells, making it easier for surgeons to determine if all cancer cells have been removed or if additional surgeries are required.

Instead of requiring patients to receive large doses of probe via IV hours before the procedure, Akrotome developed something that could be easily sprayed on the tumor area to reveal traces of remaining cancer cells. Results are available in minutes and the patient does not need to be injected with probe.

While the probes can also be administered via IV, the external and topical applications of the probes mean they have fewer U.S. Food and Drug Administration (FDA) regulatory hurdles than competing probes and can reach the market faster and at a much lower cost.

Akrotome has a portfolio of probes that target cathepsins, cancer-associated enzymes that are expressed by 85 percent of solid tumors. Trials conducted by the company indicate the probe can highlight cancer cells with better than 95 percent accuracy. The probes and technologies were developed in the laboratories of Matthew Bogyo, Ph.D., at Stanford University and James Basilion, Ph.D., at Case Western Reserve University, with imaging capabilities provided by Indec Systems Inc.

Akrotome is currently moving its probes forward for use in skin and breast cancers. Future targets include colon, ovarian and lung tumors.

Research is supported by the National Cancer Institute of the National Institutes of Health under Award Number 2R44CA180296-02.

Related Content

Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...